Empowering adolescents living with perinatally-acquired HIV: tailored CD4+ count assessment for optimized care, the EDCTP READY-study
Authors: Togna Pabo Willy Le Roi , Kengni Ngueko Aurelie Minelle , Nka Alex Durand , Santoro Maria Mercedes , Bouba Yagai , Chenwi Collins Ambe , Ngoufack Jagni Semengue Ezéchiel , Takou Désiré , Teto Georges , Dambaya Beatrice , Nyasa Raymond Babila , Tommo Tchouaket Michel Carlos , Beloumou Grace Angong , Djupsa Ndjeyep Sandrine Claire , Ka’e Aude Christelle , Tekoh Tatiana Anim Keng , Ayuk Ngwese Derrick Tambe , Etame Naomi-Karell , Mundo Rachel Audrey Nayang , Kamgaing Rachel Simo , Sosso Samuel Martin , Ndip Roland Ndip , Colizzi Vittorio , Cecchereni-Silberstein Francesca , Ndjolo Alexis , Fokam Joseph 
Published: September 2024

BackgroundThe elevated rate of AIDS-related mortality in Sub-Saharan Africa among adolescents living with HIV (ALHIV) is influenced by various factors, notably immunosuppression, within a framework of limited therapeutic alternatives. We aimed to enhance the management of pediatric HIV by assessing the immune response and associated factors in perinatally-infected ALHIV on antiretroviral therapy (ART) in Cameroon.MethodsA cohort study was conducted from 2018–2020 among 271 ART-experienced ALHIV in Cameroon. Sociodemographic data, immunological (CD4), and virological (plasma viral load, PVL) responses were measured at enrolment (T0), 6-months (T1), and 12-months (T2) using PIMA CD4 (Abbott/Pantech (Pty) Ltd) and Abbott Applied Biosystem platform (Real-Time PCR m2000RT) respectively. Immunological failure (IF) was defined as absolute CD4 &lt; 250 cells/mm3, and Virological failure (VF) as PVL ≥ 1,000 copies/ml. A linear mixed-effects model with R version 4.4.1 was used to estimate both fixed and random effects, with significance set at p &lt; 0.05.ResultsOf the 271 perinatally-infected ALHIV enrolled over three phases, females were predominant (55.7, 55.1, and 56.0%); median age was 14 (IQR: 12–17); majority of the participants were followed-up in urban areas (77.5, 74.5, and 78.6%); and the age distribution favored older adolescents (48.7, 61.2, and 58.5%). Most participants achieved clinical success (93.1, 89.7, 88.9%), predominantly on first-line ART (80.8, 66.2, and 53.0%), with good adherence (64.2, 58.9, and 64.5%). Most participants had secondary education (67.2, 70.1, and 67.5%). Median CD4+ counts fluctuated overtime, with values of 563 (IQR: 249.0–845.0), 502 (IQR: 319.0–783.5), and 628 (IQR: 427.5–817.5), respectively. Of note, being male was linked to a reduction in CD4+ count compared to females, [−200.63 (−379.32 to −21.95), p = 0.028]. Similarly, late adolescence was associated with lower CD4+ counts compared to early adolescence, [−181.08 (−301.08 to −61.09), p = 0.003]. Moreover, participants experiencing VF showed significantly lower CD4+ counts compared to those with undetectable viral loads, [−353.08 (−465.81 to −240.36), p &lt; 0.001]. Additionally, there was a marginally significant interaction between male gender and secondary educational level, [209.78 (−6.94–426.51), p = 0.058].ConclusionAmong perinatally-infected ALHIV, age, gender, educational level, and virological status are key factors influencing their immune health and treatment outcomes. Prioritizing targeted interventions and close monitoring within these subgroups is crucial for optimal management, employing holistic care strategies that consider not only medical interventions but also psychosocial support and education.